Research Services

Cell Technology, working in collaboration with Dr. Michael Corey, has developed a novel non-radioactive assay to effectively conduct the study with significantly less time compared to radioactive Chromium Release Methods (CR51).

Cell Technology has combined experience of over 30 years in conducting ADCC contract services for our prestigious clients. We provide ADCC/CDC assay services to determine the activity of the antibody and/or complement against specified target cell lines. The result would be a dose-dependent kinetic response of the therapeutic antibody. The assay service includes optimization of E/T ratios, measurement of ADCC / CDC activity at a series of antibody concentrations, at a certain E:T ratio. Correlation data with FACS analysis can be generated upon request.

About Cell Technology

Cell Technology possesses a customizable ADCC/CDC/CMC assay platform that facilitates the selection of antibody drug candidates. Our bioluminescent ultra sensitive aCella-TOX Assay, is rapidly becoming the standard for ADCC/CDC/CMC assays within the therapeutics industry. Please click here for a direct comparison between the aCella-TOX and (51Cr) Chromium Release Methods

We provide ADCC/CDC assay services to determine the activity of the antibody and/or complement against specified target cell lines . The result would be, a dose dependent kinetic response of the therapeutic antibody. The assay service includes optimization of E/T ratios, measurement of ADCC / CDC activity at a series of antibody concentrations, at a certain E:T ratio

Correlation data with FACS analysis can be generated upon request.

About Cell Technology

In ADCC, natural killer (NK) cells, neutrophils and macrophages bind antibody-coated cells by receptors that recognize the constant region of immunoglobulin (Fcγ receptors, FcγRs). CD16 (FcγRIII) is a low affinity Fc receptor expressed on the surface of NK cells. Binding mediated by the FcγRIIIA receptor(CD16A, encoded by FCGR3A) plays an important role in NK cell activation. Cell Technology Inc. offers CD16 phenotyping services based on allelic polymorphism in NK cell FcγRIIIA at Phe158/Val158 which may influence affinity of Mab Fc-binding and antibody therapeutic efficacy.

We developed a flow cytometry-based test for this polymorphism using a mAb that recognized only the FcγRIIIA-158 V allele (antibody 1) in combination with a mAb that detected both FcγRIIIA-158 alleles (antibody 2). The ratio between the mean fluorescence intensity (MFI) measured with those mAbs (Table 1) in a single individual predicted the FCGR3A genotype with 100% sensitivity and specificity.

The service provides highly customized solutions designed to meet your specific research needs. It is a considerably faster, efficient and cost-effective phenotyping program which enables broad spectrum analysis of the specific ADCC responses in patients and the therapeutic efficacy of antibody drugs.

Close Bitnami banner
Bitnami